Heart pump implant combined with gene therapy in new trial

Celladon ($CLDN) has announced the beginning of a trial it hopes will determine the feasibility of using MYDICAR in heart failure patients using left ventricular assist devices (LVADs). MYDICAR, a treatment that uses targeted gene therapy to improve the heart's ability to pump blood, yielded positive results in previous trials with heart failure patients. The company hopes MYDICAR can provide a new option for patients with LVADs who have essentially exhausted all other treatment options, Celladon CEO Krisztina Zsebo said in a statement. Part of the funding from the trial will come from the British Heart Foundation, and it is being sponsored by the Imperial College of London. Release

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.